[{"id":"0005db66-97a2-46a0-8192-8f0061bcd96d","acronym":"KEYNOTE-A62","url":"https://clinicaltrials.gov/study/NCT04336098","created_at":"2021-01-18T20:59:34.166Z","updated_at":"2025-02-25T16:10:09.652Z","phase":"Phase 1","brief_title":"Study of SRF617 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04336098 - KEYNOTE-A62","lead_sponsor":"Coherus Biosciences, Inc.","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • gemcitabine • albumin-bound paclitaxel • perenostobart (SRF617)"],"overall_status":"Completed","enrollment":" Enrollment 85","initiation":"Initiation: 03/16/2020","start_date":" 03/16/2020","primary_txt":" Primary completion: 08/25/2023","primary_completion_date":" 08/25/2023","study_txt":" Completion: 08/25/2023","study_completion_date":" 08/25/2023","last_update_posted":"2024-06-04"},{"id":"f40873ca-e3ed-4dcf-90c0-5527c131aaed","acronym":"","url":"https://clinicaltrials.gov/study/NCT05891171","created_at":"2023-06-06T14:07:07.271Z","updated_at":"2024-07-02T16:35:01.204Z","phase":"Phase 1","brief_title":"Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers","source_id_and_acronym":"NCT05891171","lead_sponsor":"Arcus Biosciences, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • 5-fluorouracil • pemetrexed • oxaliplatin • Yutuo (zimberelimab) • leucovorin calcium • AB598"],"overall_status":"Recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 10/13/2023","start_date":" 10/13/2023","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-05-24"},{"id":"c0a06349-a221-453f-bcd3-a07338de124e","acronym":"MATISSE","url":"https://clinicaltrials.gov/study/NCT05742607","created_at":"2023-02-24T16:01:14.327Z","updated_at":"2024-07-02T16:35:14.384Z","phase":"Phase 2","brief_title":"IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)","source_id_and_acronym":"NCT05742607 - MATISSE","lead_sponsor":"Innate Pharma","biomarkers":" EGFR • PD-L1 • ALK","pipe":"","alterations":" ","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • IPH5201"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 06/23/2023","start_date":" 06/23/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-03-15"},{"id":"b27e5854-9657-4b24-a83c-b4bf33177792","acronym":"","url":"https://clinicaltrials.gov/study/NCT03884556","created_at":"2021-01-18T19:08:40.399Z","updated_at":"2025-02-25T16:15:48.685Z","phase":"Phase 1","brief_title":"TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers","source_id_and_acronym":"NCT03884556","lead_sponsor":"Trishula Therapeutics, Inc.","biomarkers":" ENTPD1","pipe":" | ","alterations":" ENTPD1 expression","tags":["ENTPD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ENTPD1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • gemcitabine • docetaxel • albumin-bound paclitaxel • eltivutabart (TTX-030)"],"overall_status":"Completed","enrollment":" Enrollment 56","initiation":"Initiation: 04/10/2019","start_date":" 04/10/2019","primary_txt":" Primary completion: 11/30/2022","primary_completion_date":" 11/30/2022","study_txt":" Completion: 09/29/2023","study_completion_date":" 09/29/2023","last_update_posted":"2023-10-04"},{"id":"d7c33d28-bc2c-488a-ae44-8439d7424f2f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05508373","created_at":"2022-08-19T17:10:11.974Z","updated_at":"2024-07-02T16:36:05.136Z","phase":"Phase 1","brief_title":"A Clinical Study to Evaluate the Safety, Tolerability,JS019 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05508373","lead_sponsor":"Suzhou Kebo Ruijun Biotechnology Co., Ltd","biomarkers":" ENTPD1","pipe":"","alterations":" ","tags":["ENTPD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JS019"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 03/29/2022","start_date":" 03/29/2022","primary_txt":" Primary completion: 06/15/2024","primary_completion_date":" 06/15/2024","study_txt":" Completion: 08/10/2024","study_completion_date":" 08/10/2024","last_update_posted":"2022-08-19"},{"id":"9e2f5cfc-1303-4139-8875-5758a715f3c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05374226","created_at":"2022-05-16T13:53:38.129Z","updated_at":"2024-07-02T16:36:10.410Z","phase":"Phase 1","brief_title":"A Phase 1 Study to Evaluate JS019 in Advanced Solid Tumors or Lymphomas","source_id_and_acronym":"NCT05374226","lead_sponsor":"Suzhou Kebo Ruijun Biotechnology Co., Ltd","biomarkers":" ENTPD1","pipe":"","alterations":" ","tags":["ENTPD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JS019"],"overall_status":"Recruiting","enrollment":" Enrollment 172","initiation":"Initiation: 03/31/2022","start_date":" 03/31/2022","primary_txt":" Primary completion: 12/11/2023","primary_completion_date":" 12/11/2023","study_txt":" Completion: 03/07/2024","study_completion_date":" 03/07/2024","last_update_posted":"2022-05-16"}]